Loading
A phase 2 trial of everolimus in colorectal cancer, run by Fudan University, not yet recruiting.
Everolimus Combined With PD-1 in Advanced Colorectal Cancer Patients is a phase 2, interventional study registered as NCT06301386 by Fudan University, with a registry enrolment figure of 25 participants, started 2024-04-01 and due to reach its primary completion in 2026-05-01. Interventions recorded: Everolimus; PD-1. Conditions listed: Colon Cancer. Primary outcome: objective response rate (ORR). Colorectal eligibility wording from the registry: "Patients with histologically or cytologically confirmed locally advanced and advanced colorectal cancer that cannot be R0 resected;". Sites: China. No results are recorded here; the registry entry is the source.
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.